Intro

This chapter features a panel of rheumatology experts discussing key highlights from the final day of a conference focused on new advancements in the field. They spotlight a significant study on Dapirulizumab and its promising results for treating moderate to severe lupus, along with various insightful discussions on other critical findings from the event.